We offer a wide range of therapy-relevant genetic testing for solid tumors.

The information serves as a guide to molecular biomarkers and targeted drugs. Due to the complexity of study results and drug approvals, the completeness of the data cannot be guaranteed. Drug treatment can only be initiated by qualified oncologists, usually based on tumor board decisions.

Overview of our range of services

To the supplement on molecular biomarkers and indications (german)

* Activating EGFR mutations are diverse. They are the subject of numerous studies that are constantly modifying treatment strategies for non-small cell lung cancer. It is not possible to provide a complete overview of the complex results here.